炎症性肠病（inflammatory bowel disease，IBD）是一种发病机制尚未明确的慢性肠道疾病，临床药物疗效有限且不良反应多，亟需开发安全、有效的治疗手段及药物，目前大量研究表明植物来源囊泡（plant-derived vesicles，PDVs）治疗IBD有巨大的潜力及开发前景，是新药研发的热点。通过综述不同来源PDVs治疗IBD的研究进展、疗效评价，发现其可通过核因子-κB、单磷酸腺苷活化的蛋白激酶等信号通路及PDVs中的微小RNA维持M₁/M₂巨噬细胞平衡、调节免疫失衡、肠道微生物稳态及修复肠道屏障等治疗IBD。并进一步探讨PDVs作为新型载药系统的潜力及开发前景，为PDVs的药用开发及治疗IBD的临床转化提供理论依据。

Inflammatory bowel disease (IBD) is a chronic intestinal disease with an unclear pathogenesis. Clinical drugs are limited and have serious side effects. There is an urgent need to develop safe and effective treatment methods and drugs. At present, a large number of studies have shown that plant derived vesicles (PDVs) have great potential and development prospects for treating IBD, and are a hot research topic in drug development. This study reviewed the research progress of PDVs from different plants for treating IBD and evaluated their efficacies. It was found that they can maintain balance of M₁/M₂ macrophage, regulate dysfunction of immune system, modulate intestinal microbiota homeostasis, and repair intestinal barriers through nuclear factor-κB, adenosine monophosphate activated protein kinase and other inflammation related signaling pathways, as well as microRNAs in PDVs for treatment of IBD. In addition, the potential and development prospect of PDVs in novel drug delivery systems have been discussed, providing theoretical basis for development of PDVs and clinical transformation of IBD treatment.

R285

湖南省卫生健康委重点课题（C202302048602）;湖南省卫生健康委一般课题（W20243256）;湖南省中医药管理局一般课题（B2024031）;湖南省自然科学基金青年项目（2024JJ6286）